The use of phenylhydrazine as a therapeutic agent followed its use experimentally in producing hepatic lesions, when destruction of the erythrocytes was noted. Hoppe-Seyler1 in 1885 was the first to employ hydrazine experimentally in animals, and in 1908 Morawitz and Pratt2 used it specifically for the purpose of producing experimental anemia in animals. Eppinger and Kloss3 in 1918 were the first to apply it clinically in cases of polycythemia vera. They observed a fall in the erythrocytes and hemoglobin, mild jaundice and dark urine. Taschenberg4 reported details of the treatment of a woman with polycythemia vera. The patient had splenomegaly; the hemoglobin was 140 per cent, and the erythrocytes numbered 8,500,000 for each cubic millimeter. She was given a total of 3 Gm. of phenylhydrazine hydrochloride over a period of thirteen days, and a year later 4.25 Gm. in twenty-one days, with definite effect on the blood and the
BROWN GE, GIFFIN HZ. THE TREATMENT OF POLYCYTHEMIA VERA (ERYTHREMIA) WITH PHENYLHYDRAZINE. Arch Intern Med (Chic). 1926;38(3):321–345. doi:10.1001/archinte.1926.00120270044004
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: